PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

NASCAR will hold a street race on Naval Base Coronado in Southern California next June as a replacement for its downtown ...

Shares of AbivaxABVX hit the stratosphere Wednesday after the small biotech unveiled "potentially disruptive" results for its ...

The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by risi ...

The One Big Beautiful Bill Act (OBBBA), signed into law by President Donald Trump on July 4, 2025, provides for enhanced restrictions on ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

U.S. stocks are rising toward another record following a trade deal between the world’s No. 1 and No. 4 economies, one that ...

Asian shares have rallied, with Tokyo's benchmark Nikkei 225 index up 3.5% after Japan and the U.S. announced a deal on ...